an expert panel recommended approval of novartis s experimental chimeric antigen t cell therapy tisagenlecleucel for children and young adults with relapsed or refractory b cell acute lymphoblastic leukemia the therapy would be the first of its kind approved for cancer and has the potential to transform standard of care for advanced blood cancers.